Profound Medical Corp.PROF

Profound Medical Corp. (TSX: PROF) just reminded shareholders that hope is not a strategy-and neither is a $7.1 million net loss for the quarter to 31 March 2026. The med-tech company booked $5.3 million in revenue, lost $8.0 million on operations, and still managed a $0.19 diluted earnings-per-share figure that owes more to share-count mechanics than to any operating miracle.

What the company does is build and sell TULSA-PRO, an MRI-guided, incision-free prostate ablation system, and Sonalleve, a CE-marked platform for non-invasive treatment of uterine fibroids and palliative pain relief in bone metastases. Both platforms sit inside a regulatory perimeter that is currently weighted toward the EU and Canada, where CE marks and Health Canada nods sit alongside the more exacting FDA process still to be crossed for US deployment.

For the three months ended 31 March 2026, Profound reported revenue of $5.3 million, net loss of $7.1 million, operating loss of $8.0 million, and stockholders’ equity of $59.4 million against $14.0 million in liabilities. Cash and equivalents stood at $50.3 million, while operating cash burn was $8.6 million, inventory rose by $996,000 to $9.0 million, and R&D spend was $5.3 million. The company’s diluted share count was 36.3 million. (source: 10-Q for the quarter ended 31 March 2026, filed 2026-05-15, https://www.sec.gov/Archives/edgar/data/1628808/000110465926062509/tm2614840-1_8k.htm)

The most recent colour from the executive suite arrives in an 8-K dated 24 July 2026, titled “Entry into a Material Definitive Agreement,” which the company frames as a financing step rather than an emergency recapitalisation. The release is light on specifics but heavy on the language of “strategic collaboration” and “capital deployment,” a phrase investors have learned to read as “we need more cash.” (source: 8-K (2026-07-24), https://www.sec.gov/Archives/edgar/data/1628808/000117184326004863/f8k_072426.htm)

The company’s clinical publications page promises “quality clinical evidence,” but the evidence that matters most to shareholders is the kind that appears on the balance sheet, not in a peer-reviewed journal. Sonalleve carries a CE mark, TULSA-PRO is cleared in Canada and parts of Europe, but neither device has yet cleared the FDA hurdle that would unlock the US market’s deeper capital pools. Until that happens, the company’s growth story is a European corridor with a side door into Canada and a long queue at the FDA elevator. (source: Clinical Publications page, https://profoundmedical.com/clinical-publications/)

If you’re looking for a readable chart route, the company’s investor site links to its quarterly results and forward-looking slide deck, not to a live trading chart. For context on equity plumbing, the TSX ticker is PROF and the latest 10-Q and 8-K filings sit on EDGAR under CIK 0001628808. (source: SEC EDGAR index for CIK 0001628808, https://www.sec.gov/edgar/browse/?CIK=1628808)

The next milestone is the second-quarter 2026 results due 6 August 2026, a date the company has already telegraphed to shareholders. Until then, the gap between the polished pitch and the prosaic P&L remains the story-and the inventory line keeps climbing. (source: Investors page, https://profoundmedical.com/news/)